Trastuzumab in Breast Cancer Treatment: Concurrent vs. Sequential
Author Information
Author(s): Verma Sunil MD MSEd FRCP
Primary Institution: Toronto–Sunnybrook Regional Cancer Centre
Hypothesis
What trastuzumab-based regimen would you suggest for this patient? A concurrent or sequential approach?
Conclusion
A concurrent approach to trastuzumab treatment appears to be more effective and has manageable cardiac toxicity compared to a sequential approach.
Supporting Evidence
- The concurrent approach was found to be superior to the sequential approach in an unplanned interim analysis.
- The pacs-04 trial showed no significant improvement in disease-free survival with the sequential approach.
- Cardiac toxicity rates were similar between concurrent and sequential approaches.
Takeaway
Doctors are trying to figure out the best way to give a medicine called trastuzumab to help breast cancer patients, and it looks like giving it at the same time as other treatments might be better and safer for the heart.
Limitations
The trials compared had different eligibility criteria and follow-up recommendations, making comparisons difficult.
Participant Demographics
The case study involves a 58-year-old woman diagnosed with invasive ductal carcinoma.
Statistical Information
P-Value
p = 0.41
Want to read the original?
Access the complete publication on the publisher's website